By Ana Espino | Published on February 26, 2026 | 3 min read
Cervical cancer remains one of the few largely
preventable cancers
thanks to organized screening programs combining cervical cytology and HPV
testing. Yet, despite these established strategies, diagnoses at advanced
stages still occur. Conventional cytology, the historical cornerstone of
screening, has intrinsic limitations. Its interpretation relies on
expert human
morphological analysis, subject to inter- and intra-observer variability.
Low-grade lesions, subtle atypia, and paucicellular samples represent
diagnostic weak points. As screening programs expand, the growing volume of
samples increases the risk of analytical fatigue and triage errors.
In this already demanding context, the introduction of
HPV testing has
transformed decision-making algorithms. More sensitive for identifying at-risk
patients, it enhances early detection. However, its
lower specificity increases
the number of follow-up examinations and complicates clinical stratification.
The challenge is therefore no longer solely to detect abnormalities, but to
accurately prioritize risk while maintaining laboratory efficiency.
Amid the transition toward more standardized and digital medicine,
artificial intelligence (AI) has emerged as a strategic lever. A review
published in 2025 in Bioengineering examined the growing integration of AI
systems in diagnostic cervical cytology, assessing their
analytical
performance, organizational potential, and clinical limitations.
Can AI reduce false negatives?
The authors conducted a narrative review based on literature from the
past five years. Thirty studies were included, primarily focusing on clinical
applications of deep learning in cervical cytology. Bibliometric analysis
revealed rapid expansion of the field, with 90% of publications occurring
within the last five years, reflecting increasing scientific interest.
Reported diagnostic performance was high. Several models based on
convolutional neural networks (CNNs) or hybrid architectures achieved
performance comparable to, or exceeding, human expertise. One model validated
in over 16,000 patients demonstrated an AUC of 0.947, with 94.6% sensitivity
and 89.0% specificity for detecting cervical lesions.
In a cohort exceeding 700,000 women, an AI system achieved 94.7%
concordance with cytologists while increasing sensitivity by 5.8%. These
findings suggest genuine potential to reduce false negatives, the principal
limitation of cytology-based screening.
Technological approaches are evolving toward multimodal models
integrating cytological images, HPV status, and molecular biomarkers.
Semi-supervised and self-supervised learning techniques allow the use of large
partially annotated image datasets. Additionally, the emergence of explainable
AI (xAI) models aims to improve decision transparency, a prerequisite for
clinical acceptance.
Commercial solutions such as the Genius™ Digital Diagnostics System,
already authorized by the FDA, illustrate the shift from experimental
development to routine implementation. AI is no longer confined to research; it
is becoming an operational tool for case triage and prioritization.
Screening enters the intelligent era
Cervical cancer remains preventable through organized screening.
However, the real-world effectiveness of such programs depends on the quality
and reproducibility of cytological interpretation, still subject to human
variability and significant analytical workload.
The current challenge extends beyond lesion detection to include
standardization, reliability, and optimization of diagnostic workflows. This
review aimed to evaluate the maturity and clinical relevance of AI applied to
cervical cytology by analyzing its diagnostic performance and integration
potential in routine practice.
Available data indicate that AI significantly improves diagnostic
sensitivity, reduces inter-observer variability, and contributes to
standardization of morphological assessment, with robust performance in large
cohorts. These findings support its role as a triage-support tool and as a
means of strengthening screening safety.
Although further multicenter validation in more diverse populations is
required, the evidence highlights the potential of AI-assisted cytology to
consolidate the performance of prevention programs. Ultimately, this approach
may enable finer risk stratification and greater efficiency in diagnostic
pathways, thereby reinforcing the long-term impact of cervical cancer
screening.
Read next: Stem cell transplantation: ai to
predict severe complications
About the author – Ana Espino
PhD in Immunology, specialized in Virology
As a scientific writer, Ana is passionate about bridging the gap
between research and real-world impact. With expertise in immunology, virology,
oncology, and clinical studies, she makes complex science clear and accessible.
Her mission: to accelerate knowledge sharing and empower evidence-based
decisions through impactful communication.
